Title : Dasatinib and navitoclax act synergistically to target NUP98-NSD1+/FLT3-ITD+ acute myeloid leukemia.

Pub. Date : 2019 Jun

PMID : 30568173






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Furthermore, NUP98-NSD1+/FLT3-ITD+ patient cells were also very sensitive to BCL2-inhibitor navitoclax, although the highest select sensitivity was found to SRC/ABL-inhibitor dasatinib (mean IC50 = 2.2 nM). Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 We found that SRC/ABL-inhibitor dasatinib is highly synergistic with BCL2-inhibitor navitoclax in NUP98-NSD1+/FLT3-ITD+ cells. Dasatinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens